John Hussman's PCRX Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 0 shares of Pacira BioSciences, Inc. (PCRX) worth $0, representing 0.00% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 16 quarters.
Based on 13F filings, John Hussman has maintained a strategic position in PCRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 105,000 shares. Largest reduction occurred in Q1 2026, reducing 126,000 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Pacira BioSciences (PCRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pacira BioSciences (PCRX) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -126,000 | Sold Out | 0 | $0.00 |
| Q4 2025 | +21,000 | Add 20.00% | 126,000 | $25.88 |
| Q3 2025 | +105,000 | New Buy | 105,000 | $25.77 |
| Q4 2024 | -21,000 | Sold Out | 0 | $0.00 |
| Q4 2023 | -5,000 | Reduce 19.23% | 21,000 | $33.74 |
| Q2 2023 | -20,800 | Reduce 44.44% | 26,000 | $40.07 |
| Q4 2022 | +46,800 | New Buy | 46,800 | $38.61 |
| Q1 2022 | -5,200 | Sold Out | 0 | $0.00 |
| Q4 2021 | -1,000 | Reduce 16.13% | 5,200 | $60.19 |
| Q3 2021 | -6,200 | Reduce 50.00% | 6,200 | $55.97 |
| Q2 2021 | +12,400 | New Buy | 12,400 | $60.65 |
John Hussman's Pacira BioSciences Investment FAQs
John Hussman first purchased Pacira BioSciences, Inc. (PCRX) in Q2 2021, acquiring 12,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Pacira BioSciences, Inc. (PCRX) for 16 quarters since Q2 2021.
John Hussman's largest addition to Pacira BioSciences, Inc. (PCRX) was in Q3 2025, adding 105,000 shares worth $2.71 M.
According to the latest 13F filing for Q1 2026, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 0 shares of Pacira BioSciences, Inc. (PCRX), valued at approximately $0.
As of the Q1 2026 filing, Pacira BioSciences, Inc. (PCRX) represents approximately 0.00% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in Pacira BioSciences, Inc. (PCRX) was 126,000 shares, as reported at the end of Q4 2025.